Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Schisandra C in the preparation of drugs for improving glucocorticoid-induced osteoporosis

A technology of schisandra C and glucocorticoids, applied in the field of medicine, can solve the problems of less research, achieve the effect of improving osteoporosis, improving glucocorticoid-induced osteoporosis, and promoting osteoblast proliferation

Inactive Publication Date: 2017-10-20
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Schisandrin C (schisandrin C) (see formula 1 for the structural formula) exists in a small amount in Schisandra medicinal materials, and there are few studies at present
Schisandra C on the regulation of osteoblasts, and its research on the prevention / treatment of glucocorticoid-induced osteoporosis has not been reported in the literature

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Schisandra C in the preparation of drugs for improving glucocorticoid-induced osteoporosis
  • Application of Schisandra C in the preparation of drugs for improving glucocorticoid-induced osteoporosis
  • Application of Schisandra C in the preparation of drugs for improving glucocorticoid-induced osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 (Schisandra C improves the study of dexamethasone-induced osteoporosis in mice)

[0030] (1) Materials and methods

[0031] (1) Experimental animals

[0032] 40 adult male ICR mice (8 weeks old, with an average body weight of 30±2g) were provided by the Experimental Animal Center of Second Military Medical University. Raised in the SPF animal experiment center, 12 hours a day, day and night, constant temperature 18 ~ 20 ℃, mice can eat and drink freely. All mice were reared for one week in advance, and the experiment was carried out after adapting to the living environment.

[0033] (2) Preparation of main reagents

[0034] 1. Dexamethasone sodium phosphate: use 0.9% sodium chloride solution to prepare a solution with a concentration of 0.25mg / ml;

[0035] 2. Schisandra C: Dissolve 20mg of Schisandra C in 2100ml of absolute ethanol, pipette until completely dissolved; dissolve 20mg of completely dissolved Schisandra C in 84ml of propylene glycol, the final...

Embodiment 2

[0048] Example 2 (the effect of Schisandra C combined with dexamethasone on the proliferation and differentiation of mouse osteoblasts)

[0049] (1) Materials and methods

[0050] Cell line: mouse osteoblast cell line (MC3T3-E1) was purchased from ATCC. The above cell lines were incubated in α-MEM medium containing 10% fetal bovine serum at 37°C with a volume fraction of 5% CO 2 , Routine culture under fully saturated humidity conditions, replace the medium for 48 hours, when the cell growth reaches saturation, digest with 0.25% trypsin + 0.02% EDTA for passage, once every 2-3 days, the experiment uses logarithmic growth phase cells.

[0051] 1. The effect of Schisandra C on the proliferation inhibition of mouse osteoblasts induced by dexamethasone

[0052] 1.1. The osteoblasts MC3T3-E1 in the logarithmic growth phase were inoculated in three 96-well plates, and the cell density was adjusted to about 5×10 3 Each culture plate is divided into 7 groups, namely ① blank control...

Embodiment 3

[0071] Embodiment 3 (preparation of schisandra acetin tablet)

[0072] Take 25g of schisandra acetone, 10g of hydroxypropyl methylcellulose, 50g of microcrystalline cellulose, 5g of croscarmellose sodium, mix well, add an appropriate amount of 60% ethanol to make a soft material, pass through a 24-mesh sieve and granulate , dried at 50°C for 2 hours, the dried granules were passed through a 30-mesh sieve for granulation, 2.5g of magnesium stearate was added, mixed evenly, and pressed into 1000 tablets respectively.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a new medical application of schisandra C, that is, the application in the preparation of medicaments for preventing or treating glucocorticoid-induced osteoporosis. Its advantages are as follows: the present invention shows for the first time through in vitro and in vivo studies that schisandra C can significantly improve osteoporosis caused by long-term use of dexamethasone, promote osteoblast proliferation, and has the ability to prepare and prevent or treat glucocorticoid-induced osteoporosis The prospect of drug application.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the new medical application of schisandra C, that is, the application of schisandra C in the preparation of drugs for the prevention / treatment of glucocorticoid-induced osteoporosis. Background technique [0002] Glucocorticoids (glucocorticoid, GC) are a class of drugs widely used clinically for the treatment of many chronic inflammatory diseases and autoimmune diseases, such as ulcerative colitis, systemic lupus erythematosus, asthma, rheumatoid arthritis etc. However, long-term application of GC often causes many side effects, among which glucocorticoid-induced osteoporosis (GIO) is one of the most serious side effects caused by GC. GIO is the most common secondary osteoporosis and can cause osteoporotic fractures. It is estimated that about 30% of patients who receive GC treatment for more than 6 months will develop osteoporosis; while about 30% to 50% of adult patients wh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/36A61P19/10
Inventor 程彬彬凌昌全程思路杜娟梁淑芳邓正亭姚曼郭玉玉孟永斌
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com